Q1 Earnings Forecast for CG Oncology Issued By HC Wainwright

CG Oncology, Inc. (NASDAQ:CGON) – Analysts at HC Wainwright dropped their Q1 2025 earnings per share (EPS) estimates for CG Oncology in a report issued on Monday, March 31st. HC Wainwright analyst A. Maldonado now anticipates that the company will post earnings of ($0.58) per share for the quarter, down from their previous forecast of ($0.46). HC Wainwright has a “Buy” rating and a $75.00 price target on the stock. The consensus estimate for CG Oncology’s current full-year earnings is ($1.31) per share. HC Wainwright also issued estimates for CG Oncology’s Q2 2025 earnings at ($0.60) EPS, Q3 2025 earnings at ($0.62) EPS, Q4 2025 earnings at ($0.64) EPS, FY2025 earnings at ($2.44) EPS, FY2026 earnings at ($2.30) EPS, FY2027 earnings at ($1.81) EPS and FY2028 earnings at ($0.15) EPS.

Several other equities analysts have also commented on the company. Morgan Stanley reaffirmed an “overweight” rating and set a $55.00 target price on shares of CG Oncology in a report on Friday, March 7th. TD Cowen started coverage on CG Oncology in a research report on Tuesday, January 7th. They set a “buy” rating for the company. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $66.00 target price on shares of CG Oncology in a research report on Friday, December 6th. Nine analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $63.88.

CG Oncology Stock Up 0.9 %

CGON opened at $22.24 on Thursday. The company’s 50-day moving average price is $27.50 and its 200 day moving average price is $31.57. CG Oncology has a fifty-two week low of $21.48 and a fifty-two week high of $46.99. The firm has a market cap of $1.69 billion, a price-to-earnings ratio of -15.66 and a beta of 1.60.

CG Oncology (NASDAQ:CGON) last issued its earnings results on Tuesday, March 25th. The company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.11). CG Oncology had a negative return on equity of 18.97% and a negative net margin of 10,642.98%. The business had revenue of $0.46 million for the quarter, compared to analyst estimates of $0.11 million.

Hedge Funds Weigh In On CG Oncology

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. lifted its holdings in shares of CG Oncology by 114.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 379,664 shares of the company’s stock valued at $14,325,000 after purchasing an additional 202,262 shares in the last quarter. The Manufacturers Life Insurance Company grew its position in CG Oncology by 21.3% during the third quarter. The Manufacturers Life Insurance Company now owns 73,149 shares of the company’s stock valued at $2,760,000 after purchasing an additional 12,848 shares in the last quarter. FMR LLC grew its stake in shares of CG Oncology by 83,581.6% in the 3rd quarter. FMR LLC now owns 145,606 shares of the company’s stock valued at $5,494,000 after buying an additional 145,432 shares in the last quarter. BNP Paribas Financial Markets lifted its stake in CG Oncology by 876.9% in the third quarter. BNP Paribas Financial Markets now owns 26,660 shares of the company’s stock valued at $1,006,000 after acquiring an additional 23,931 shares during the last quarter. Finally, MetLife Investment Management LLC grew its position in CG Oncology by 103.2% in the third quarter. MetLife Investment Management LLC now owns 27,132 shares of the company’s stock worth $1,024,000 after acquiring an additional 13,780 shares in the last quarter. 26.56% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director Leonard E. Post sold 1,000 shares of the business’s stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $29.66, for a total transaction of $29,660.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.